Business Wire

pixitmedia Integrates Ngenea® Data Acceleration Software Into Nara

Share

pixitmedia, a subsidiary of Kalray (Euronext Growth Paris: ALKAL) specializing in storage and data management solutions for the Media & Entertainment industry, announced that it has integrated its flagship data acceleration platform, Ngenea®, intoFilmLight’s Nara media tool. By enabling media professionals to instantly push assets from point A to B directly through the Nara interface, the new Ngenea for Nara plugin maximizes efficiency in moving image content creation, further streamlining workflows for video and film projects, and freeing time for heightened creativity.

pixitmedia is showcasing Ngenea + Nara at IBC 2024 Amsterdam, September 13 – 16, in its booth at Hall 5.H79.

FilmLight, maker of the Baselight grading system, offers Nara to enable integrated media access, streaming and indexing to streamline workflows and enhance collaboration. Managing file access and security is an ongoing challenge that can constrain efficient workflows and storage resource budgets. With Ngenea integrated into Nara, editors, colorists, visual effects (VFX) artists, cinematographers and directors boost productivity across the most demanding use cases in their workflows.

The Ngenea for Nara plugin enables media professionals to orchestrate production assets between sites and storage classes using Ngenea in real-time, avoiding the delays and bottlenecks that impede efficient workflows. It allows users with Nara to push assets to a central facility instantly – or, when Nara is deployed across multiple locations, to move assets in line with the workflow, or following talent across geographies.

“We launched Nara to empower our customers by boosting their efficiency and creativity, and pixitmedia’s Ngenea for Nara plugin fully supports this mission,” said Sam Lempp, Nara’s head of business development. “We’re delighted to be working with pixitmedia on this Nara and Ngenea integration and to be able to offer our customers yet another efficient workflow tool which will further boost their productivity.”

Built on a foundation of pixitmedia’s underlying software-defined storage platform, Ngenea enables customers to accelerate the processing of their data and streamline complex workflows.

Compatible with both on-prem and cloud environments, Ngenea, enables teams to stream in real-time to Nara’s powerful playback engine or for content delivery either internally or to secure sites of collaborators. Users can automate the process of selecting individual shots, and orchestrate media using Ngenea to any of its supported storage targets, including S3 and most NAS filer, without leaving the Nara interface. Working directly in the web browser, media professionals unlock new levels of agility, backed by the low latency performance needed by Nara to stream and encode in real time to a Nara client.

“pixitmedia is committed to doing whatever it takes to support media & entertainment teams in working at peak efficiency with their preferred solutions, said Eric Baissus, CEO of Kalray, parent to pixitmedia. “The Ngenea for Nara plugin helps media professionals to make the most of their existing technology investments so they can save time, lower costs, and deliver exceptional creative work.

The Ngenea for Nara plugin is available now from pixitmedia. For more information visit www.pixitmedia.com.

ABOUT NARA

Nara, a FilmLight venture, is an integrated media tool offering a streamlined and sophisticated solution for media access, streaming and indexing. Nara can natively decode and play back a wide selection of media without the need to transcode to proxy files. Its advanced indexing system ensures rapid data retrieval while its streaming engine minimises bandwidth usage. It supports on premise and in the cloud storage, provides unparalleled codec support and guarantees uniform and colour-accurate image presentation – offering a comprehensive, efficient, and consistent media review experience which improves workflows and enhances collaboration.

Nara utilizes the technological foundation and expertise of FilmLight and the proven technology that powers its industry-leading Baselight grading platform. For more information, visit: www.nara.stream

ABOUT KALRAY

Kalray is a technology innovator specializing in software and hardware solutions to accelerate data-intensive workflows in Media & Entertainment, High-Performance Computing, and Artificial Intelligence. Our comprehensive product range features Ngenea, a leading data acceleration platform, and accelerated data processing cards for storage and compute.

With Kalray solutions, customers can scale their infrastructures to efficiently meet performance and capacity needs for data-intensive tasks, all without being tied to specific data formats or vendors.

Founded in 2008 as a spin-off from the French CEA research lab, Kalray has corporate and financial backing from notable investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors, and Bpifrance. Committed to innovation and excellence, we strive to deliver value to our customers, developers, and the planet through technology and expertise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910076987/en/

Contacts

INVESTOR CONTACTS

Eric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone +33 4 76 18 90 71

ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone + 33 1 53 67 36 72

PRESS CONTACTS

Penta STANLEY
communication@kalrayinc.com
Phone +44 7939 877 880

ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone +33 4 72 18 04 92

Mary Kae MARINAC
PR Representative for Kalray
mk@mkmarinac.com
Phone +1 978-685-3136

Caroline Shawley
PR Representative for Nara
carolines@filmlight.ltd.uk
Phone +44 7730 145 759

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press Release

Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield. “Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue

LambdaTest Unveils Next-Generation SmartUI Experience for Visual Testing23.12.2024 17:00:00 CET | Press Release

LambdaTest, a leading cloud-based unified testing platform has announced the general availability of its reimagined SmartUI screenshot page. This new update is all set to transform visual testing workflows, delivering a seamless, intuitive, and powerful experience tailored to the needs of testers and developers worldwide. The redesigned SmartUI interface introduces groundbreaking enhancements that prioritize user efficiency and precision. From the new pinch-to-zoom functionality for precise screenshot inspection to a streamlined navigation system featuring a side drawer for quick browsing, every detail has been thoughtfully crafted to improve productivity. The refreshed design also offers a cleaner, more spacious layout, ensuring that users can focus on what matters most—their screenshots. Smarter workflows now empower users with an intuitive grouping of related functions, while effortless variant switching simplifies the process of comparing test results. The upgraded keyboard shortcu

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases23.12.2024 13:00:00 CET | Press Release

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co., Ltd. (Representative Corporate Officer and CEO: Haruo Naito; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases. Fujirebio and Eisai have been conducting joint research on cerebrospinal fluid biomarkers related to Alzheimer’s disease (AD). The two companies have agreed to move forward with their partnership based on the shared understanding that the development and commercialization of diagnostic methods for neurodegenerative diseases can be accelerated by integrating the long-standing respective expertise of Fujirebio, which has experience in the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye